Almitas Capital LLC Acquires New Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Almitas Capital LLC acquired a new stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 1,050,520 shares of the company's stock, valued at approximately $672,000. Almitas Capital LLC owned 0.36% of Lyell Immunopharma at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of LYEL. Jane Street Group LLC grew its position in shares of Lyell Immunopharma by 63.7% in the 3rd quarter. Jane Street Group LLC now owns 287,717 shares of the company's stock worth $397,000 after buying an additional 111,917 shares during the last quarter. Barclays PLC raised its holdings in Lyell Immunopharma by 312.7% in the 3rd quarter. Barclays PLC now owns 240,615 shares of the company's stock worth $332,000 after purchasing an additional 182,315 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Lyell Immunopharma by 102.8% in the 4th quarter. SG Americas Securities LLC now owns 116,748 shares of the company's stock worth $75,000 after purchasing an additional 59,182 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Lyell Immunopharma by 43.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,645,787 shares of the company's stock valued at $1,053,000 after buying an additional 498,417 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in Lyell Immunopharma by 347.8% in the fourth quarter. JPMorgan Chase & Co. now owns 433,265 shares of the company's stock worth $277,000 after buying an additional 336,516 shares in the last quarter. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Richard Klausner purchased 158,000 shares of the business's stock in a transaction on Friday, March 14th. The stock was acquired at an average price of $0.60 per share, for a total transaction of $94,800.00. Following the acquisition, the director now directly owns 843,365 shares of the company's stock, valued at $506,019. This represents a 23.05 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Sumant Ramachandra acquired 200,000 shares of the company's stock in a transaction on Friday, March 21st. The stock was acquired at an average cost of $0.58 per share, with a total value of $116,000.00. Following the completion of the purchase, the director now directly owns 200,000 shares in the company, valued at approximately $116,000. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 768,640 shares of company stock valued at $449,508. Corporate insiders own 25.10% of the company's stock.

Lyell Immunopharma Stock Down 5.8 %

Shares of NASDAQ:LYEL traded down $0.03 during midday trading on Monday, reaching $0.43. The company's stock had a trading volume of 267,681 shares, compared to its average volume of 1,039,325. Lyell Immunopharma, Inc. has a 12-month low of $0.39 and a 12-month high of $2.88. The firm has a market capitalization of $128.32 million, a P/E ratio of -0.55 and a beta of -0.25. The firm has a 50 day moving average of $0.53 and a 200-day moving average of $0.70.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.52). Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. The business had revenue of $0.01 million for the quarter. On average, research analysts predict that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "neutral" rating and issued a $1.00 target price on shares of Lyell Immunopharma in a research note on Wednesday, April 16th.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.